Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype
- PMID: 9242542
Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype
Abstract
We analyzed a genetic polymorphism of Fc gamma receptor IIIa (CD16) that is present on position 158 (Phe or Val) in the membrane-proximal, IgG-binding domain. With a polymerase chain reaction-based allele-specific restriction analysis assay we genotyped 87 donors and found gene frequencies of 0.57 and 0.43 for Fc gammaRIIIA-158F and -158V, respectively. A clear linkage was observed between the Fc gammaRIIIA-158F and -48L genotypes on the one hand and the Fc gammaRIIIA-158V and -48H or -48R genotypes on the other hand (chi2 test; P < .001). To determine the functional consequences of this Fc gammaRIIIa-158V/F polymorphism, we performed IgG binding experiments with natural killer (NK) cells from genotyped donors. All donors were also typed for the recently described triallelic Fc gammaRIIIa-48L/R/H polymorphism. NK cells were treated with lactic acid to remove cell-associated IgG. Fc gammaRIIIa(NK)-158F bound significantly less IgG1, IgG3, and IgG4 than did Fc gammaRIIIa(NK)-158V, irrespective of the Fc gammaRIIIa-48 phenotype. Moreover, freshly isolated NK cells from Fc gammaRIIIa-158VV individuals carried significantly more cytophilic IgG than did NK cells from Fc gammaRIIIa-158FF individuals. In addition, CD16 monoclonal antibody (MoAb) MEM154 bound more strongly to Fc gammaRIIIa-158V, compared with -158F, again independently of the Fc gammaRIIIa-48 phenotype. The binding of MoAb B73.1 was not influenced by the Fc gammaRIIIa-158V/F polymorphism, but proved to depend solely on the amino acid present at position 48 of Fc gammaRIIIa. In conclusion, the previously reported differences in IgG binding among the three Fc gammaRIIIa-48L/R/H isoforms are a consequence of the linked, biallelic Fc gammaRIIIa-158V/F polymorphism at amino-acid position 158.
Similar articles
-
The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus.Arthritis Rheum. 1998 Oct;41(10):1813-8. doi: 10.1002/1529-0131(199810)41:10<1813::AID-ART13>3.0.CO;2-6. Arthritis Rheum. 1998. PMID: 9778222
-
A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa.J Immunol. 1996 Apr 15;156(8):2948-55. J Immunol. 1996. PMID: 8609432
-
The loss of the CD16 B73.1/Leu11c epitope occurring in some primary immunodeficiency diseases is not associated with the FcgammaRIIIa-48L/R/H polymorphism.Int J Mol Med. 2010 Sep;26(3):435-42. Int J Mol Med. 2010. PMID: 20664961
-
Receptors for the Fc fragment of IgG on natural killer cells.Nat Immun. 1993 Jul-Oct;12(4-5):218-34. Nat Immun. 1993. PMID: 8257828 Review.
-
Functional CD32 molecules on human NK cells.Leuk Lymphoma. 1999 Sep;35(1-2):47-56. doi: 10.3109/10428199909145704. Leuk Lymphoma. 1999. PMID: 10512162 Review.
Cited by
-
Mechanisms of action of therapeutic antibodies for cancer.Mol Immunol. 2015 Oct;67(2 Pt A):28-45. doi: 10.1016/j.molimm.2015.04.002. Epub 2015 Apr 23. Mol Immunol. 2015. PMID: 25911943 Free PMC article. Review.
-
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.Leukemia. 2017 Feb;31(2):459-469. doi: 10.1038/leu.2016.194. Epub 2016 Jul 20. Leukemia. 2017. PMID: 27435001
-
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.Clin Cancer Res. 2012 Jun 15;18(12):3478-86. doi: 10.1158/1078-0432.CCR-11-2294. Epub 2012 Apr 13. Clin Cancer Res. 2012. PMID: 22504044 Free PMC article. Clinical Trial.
-
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.Haematologica. 2012 Jun;97(6):937-42. doi: 10.3324/haematol.2011.050419. Epub 2012 Jan 22. Haematologica. 2012. PMID: 22271896 Free PMC article. Clinical Trial.
-
Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.Immunotargets Ther. 2015 May 15;4:91-100. doi: 10.2147/ITT.S61292. eCollection 2015. Immunotargets Ther. 2015. PMID: 27471715 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases